Evidence map›Paper›PMID 25455094›Full record

ArticleJournal of neuroimmunology2014

A dual vaccine against influenza & Alzheimer's disease failed to enhance anti-β-amyloid antibody responses in mice with pre-existing virus specific memory.

Hayk Davtyan, Anahit Ghochikyan, Armine Hovakimyan, Arpine Davtyan, Richard Cadagan, Annette M Marleau, Randy A Albrecht, Adolfo García-Sastre, Michael G Agadjanyan

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuroimmunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Hayk DavtyanDepartment of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647, USA.
Anahit GhochikyanDepartment of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647, USA.
Armine HovakimyanDepartment of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647, USA.
Arpine DavtyanDepartment of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647, USA.
Richard CadaganDepartment of Microbiology, Mount Sinai School of Medicine, New York, NY 10029, USA; Global Health and Emerging Pathogens Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.
Annette M MarleauDepartment of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647, USA.
Randy A AlbrechtDepartment of Microbiology, Mount Sinai School of Medicine, New York, NY 10029, USA; Global Health and Emerging Pathogens Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.
Adolfo García-SastreDepartment of Microbiology, Mount Sinai School of Medicine, New York, NY 10029, USA; Global Health and Emerging Pathogens Institute, Mount Sinai School of Medicine, New York, NY 10029, USA; Department of Medicine, Division of Infection Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA.
Michael G AgadjanyanDepartment of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647, USA; University of California, Irvine, Institute for Memory Impairments and Neurological Disorders, Irvine, CA 92697, USA. Electronic address: magadjanyan@immed.org.
Institute for Molecular Medicine · USIcahn School of Medicine at Mount Sinai · US

Funding

Combining AD Epitope Vaccine with Innate ImmunityR01NS050895 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI AGADJANYAN, MICHAEL G, CRIBBS, DAVID HASTINGS · 2004 to 2018
$7.4M
Multiple Approaches to Abeta Vaccination in Animal ModelsR01AG020241 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI AGADJANYAN, MICHAEL G, CRIBBS, DAVID HASTINGS · 2001 to 2016
$5.6M
Immunogenicity & efficacy of chimeric flu virus expressing Ab42 B cell epitopeR01NS057395 · NINDS · INSTITUTE FOR MOLECULAR MEDICINE · PI AGADJANYAN, MICHAEL G · 2008 to 2012
$2.0M
NIAID NIH HHS HHSN266200700010CNIA NIH HHS R01 AG020241NIA NIH HHS R01-AG020241NINDS NIH HHS R01 NS050895NINDS NIH HHS R01-NS050895NINDS NIH HHS R01 NS057395NINDS NIH HHS R01-NS057395
6 · The paper itself

Abstract

Novel dual vaccine, WSN-Aβ(1-10), based on the recombinant influenza virus, expressing immunodominant B-cell epitope of β-amyloid, simultaneously induced therapeutically potent anti-Aβ and anti-influenza antibodies. In this study we showed that boosting of WSN-WT primed mice with WSN-Aβ(1-10) enhances anti-viral, but fails to induce anti-Aβ antibody responses. This inhibition is associated with expression of Aβ(1-10) within the context of an inactivated influenza virus vaccine. These results demonstrate that the use of an inactivated influenza virus as a carrier for AD vaccine may not be applicable due to the possible inhibition of anti-Aβ antibody response in individuals previously vaccinated or infected with influenza.

Indexed as

Alzheimer DiseaseAlzheimer VaccinesAmyloid beta-PeptidesAnalysis of VarianceAnimalsAntibodiesDisease Models, AnimalEnzyme-Linked Immunosorbent AssayFemaleFlow CytometryHemagglutination Inhibition TestsHumansInfluenza, HumanLymphocyte ActivationLymphocytesMiceAlzheimer VaccinesAmyloid beta-PeptidesAntibodiesAlzheimer's diseaseDual vaccineImmune responsesInfluenzaMemory T cells

Identifiers

PMID25455094
PMCPMC4314405
OpenAlexW1981552560

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.